MDBIF - Rocket ship time!

?awt_l=Dx3Vy&awt_m=hw4UdQxWrQvde4A Good Morning Subscribers, The time has come for another alert with some MASSIVE potential for upside in the very near term... Our alert this morning is MDBIF MDBIFis focused on changing the way the world sees and treats mental health. We are unfortunately living in a world where many people are scared to leave their homes because of mass shootings. It's imperative to respond to mental health on this grand level and to also acknowledge and treat anyone in the world who is suffering. Truven Health Analytics Inc. has found that mental and substance use disorders treatment spending from all public and private sources is expected to total a whopping $280.5 billion in 2020, which is an increase from $171.7 billion in 2009. These amounts even include the effects of the Affordable Care Act. This is a very big arena where there is a lot of money is being spent! What MDBIFis doing could be revolutionary for the industry as the company has an innovative approach to helping diagnose. Plus the fact that MDBIFis trading at just around a PENNY could be very opportunistic for our subscribers.... Quickly add the stock to your radar now! Medibio Limited (OTC: MDBIF) [( Medibio Limited (OTC: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. The Company was founded in Australia, with offices in Australia and Minneapolis, MN, U.S. Today, mental health assessments rely on patient reporting of symptoms which are by nature, subjective. Such subjectivity often impacts symptom reporting. MDBIF's technology empowers clinicians to aid in early detection of mental health conditions and empowers individuals to screen and better understand their mental health. The company partners with healthcare industry leaders to: - License its platform and intellectual property - Collaborate on product development - Discover new applications of technology in healthcare MDBIF's approach exploits features of cardiovascular physiology influenced directly by the autonomic nervous system and susceptible to perturbation during sleep, as a source of biomarkers that correlate with onset and existence of mental dysfunction. The company's data science approach focuses on using artificial intelligence to identify mental illness phenotypes and potential physiological markers, so that it can predict dysregulation of the autonomic nervous system and future recurrent episodes. Heart rate follows a circadian rhythm with observable patterns over the course of a 24 - hour period. MDBIF uncovers insights from sleeping heart rate patterns to aid in early detection and screening of mental wellness. These are the patterns that distinguish mental illness are most obvious during sleep! The company's approach relies on identifying these heart rate patterns generated by the Autonomic Nervous Symptom (ANS) while sleeping. Diagnosis is the FIRST step in helping patients. There are a wide range of mental health conditions that not only affect mood, thinking and behavior but also make people miserable and cause problems in their daily lives. It's a stressful world and some of the most stressed out people are the ones heading to work each day. MDBIF is behind the very FIRST biometric, data-driven mental well-being monitoring and management program offering employees personalized recommendations for health and performance. It's called ilumen. ilumen™ provides data-driven feedback to help employees take an active role in their own mental well-being. By providing those in your organization with the tools to understand the difference between a bad mood and a potentially serious health threat, you strengthen and support, empowering greatness from within. Help build the strength of your workforce bringing science, not stigma, to the conversation around mental well-being and improving the lives of all that work to make your organization a success. Features include: - Employee access to ilumen™ - Mental wellness survey and assessment - Biometric monitoring with history tracking - Individual results, delivered to participants’ device - Personalised results-based recommendations including access to wellness resources - Communications toolbox for rollout - Organisational dashboard analytics - Recommendations for employer According to the World Health Organization, mental Health is one of the leading causes of disability worldwide. ilumen offers a 3 step way to help employees manage their mental wellness. - Take the Survey - Connect the Device - Discover and Manage It is already available on Google Play and in the Apple App Store. It was last fall thatMDBIFannounced its new CEO and Managing Director- David B. Kaysen. Kaysen has over 35 years of experience leading and managing both domestic and international emerging growth companies and has achieved consistent and solid results with bio-pharmaceutical, medical device, and clinical software/IT companies. He is experienced in the FDA approval process and leading products in revenue growth. He previously served as President, CEO and director of Sun BioPharma, Inc., a biopharmaceutical company developing a drug for pancreatic cancer. During his tenure, he successfully completed a reverse merger to form a U.S. publicly traded company, strengthened organization structure with public company experience in key leadership and board roles, and raised in excess of $9 million to advance the lead candidate drug into clinical trials in the U.S. and Australia! Kaysen also previously served as President, CEO and director of Uroplasty, Inc., a Minnesota-based publicly traded global medical device company, which he guided through successful clinical trials and grew annual sales from $6.7M in 2007 to $22M in 2013. He also successfully completed four rounds of financing, raising $26.5M to fund company growth. Additionally he has served as President, CEO, and director of Advanced Duplications Services, LLC; President, Chief Executive Officer and a director of Diametrics Medical, Inc., and President, CEO, and director of Rehabilicare, Inc., a global rehabilitation and neuromodulation company, where he grew sales from $4M to $73M in sales over a ten-year period. Talk about notable achievements! To have Mr. Kaysen leading MDBIF is very encouraging! By 2021, App Annie says the app market will be worth $6.3 trillion. There is still plenty of money to be made in apps and MDBIF could have an app that may be useful to millions of employees across the world! Hurry and start your research right away and put the stock on your watch list! At around just a penny, MDBIF could have stupendous potential for gains in the triple digitsat these levels. Medibio Limited (OTC: MDBIF) may be our next play to deliver monstrous rewards for our readers! GET READY! - DW Editor GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY THE FOLLOWING NOTICE AND DISCLAIMER MUST BE READ AND UNDERSTOOD AND YOU MUST AGREE TO THE TERMS CONTAINED THEREIN BEFORE USING THIS WEBSITE OR SUBSCRIBING TO OUR NEWSLETTER. We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of DearWallstreet.com nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on DearWallstreet.com. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. DearWallstreet.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. DearWallstreet.com on occasion get's retained by an unrelated third party to perform promotional and advertising services for a limited time with respect to the companies we are profile or discuss in this email and in exchange for such services we receive cash compensation from such third party. We have NOT been compensated for any marketing efforts regarding the current company profiled: MDBIF. Questions regarding this website may be sent to info@DearWallstreet.com. Some of the content on this website contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of a company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results. Generally, the information regarding a company profiled or discussed on this website is provided from public sources. DearWallstreet.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and DearWallstreet.com has no obligation to update any of the information provided. DearWallstreet.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. DearWallstreet.com encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content. DearWallstreet.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does DearWallstreet.com control, endorse, or guarantee any content found in such sites. DearWallstreet.com does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that DearWallstreet.com, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that DearWallstreet.com, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. DearWallstreet.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm. Income Disclaimer: Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions. DearWallstreet.com has not been compensated for this email. Rua Frei Tomé de Jesus n. 18 1 dto. Lisboa Lisboa 1700-215 PORTUGAL [Unsubscribe]( | [Change Subscriber Options](